Management of vaccinations in patients with <scp>non‐Hodgkin</scp> lymphoma-Reference-Cited by-同舟云学术

Management of vaccinations in patients with non‐Hodgkin lymphoma

Published:2024-03-26 Issue:5 Volume:204 Page:1617-1634
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Merli Michele¹^ORCID,Costantini Andrea²,Tafuri Silvio³^ORCID,Bavaro Davide Fiore⁴,Minoia Carla⁵,Meli Erika⁶,Luminari Stefano⁷⁸^ORCID,Gini Guido⁹^ORCID

Affiliation:

1. Division of Hematology Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan Italy

2. Clinical Immunology Unit Azienda Ospedaliero Universitaria delle Marche ‐ Università Politecnica delle Marche Ancona Italy

3. Department of Biomedical Sciences and Human Oncology Aldo Moro University of Bari Bari Italy

4. Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases Aldo Moro University of Bari Bari Italy

5. Hematology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari Italy

6. Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy

7. Hematology Unit Azienda USL‐IRCCS di Reggio Emilia Reggio Emilia Italy

8. Surgical Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine University of Modena and Reggio Emilia Modena Italy

9. Clinic of Hematology Azienda Ospedaliero Universitaria Delle Marche – Università Politecnica Delle Marche Ancona Italy

Abstract

SummaryVaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non‐Hodgkin lymphomas (NHLs). The COVID‐19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life‐threatening SARS‐CoV‐2‐related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine‐induced immune responses after anti‐CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID‐19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team‐based recommendations for the management of vaccines in this specific group of patients.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19422

Reference122 articles.

1. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities

2. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

3. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

4. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews

5. Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma;British Journal of Haematology;2024-07-22